|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Sildenafil#Contraindications]] |
| {{Sildenafil}}
| |
| {{CMG}}; {{AE}} {{AK}}
| |
| | |
| ==CONTRAINDICATIONS==
| |
| | |
| Consistent with its known effects on the nitric oxide/cGMP pathway (see CLINICAL PHARMACOLOGY), VIAGRA was shown to potentiate the hypotensive effects of nitrates, and its administration to patients who are using organic nitrates, either regularly and/or intermittently, in any form is therefore contraindicated.
| |
| | |
| After patients have taken VIAGRA, it is unknown when nitrates, if necessary, can be safely administered. Based on the pharmacokinetic profile of a single 100 mg oral dose given to healthy normal volunteers, the plasma levels of sildenafil at 24 hours post dose are approximately 2 ng/mL (compared to peak plasma levels of approximately 440 ng/mL) (see CLINICAL PHARMACOLOGY: Pharmacokinetics and Metabolism). In the following patients: age >65, hepatic impairment (e.g., cirrhosis), severe renal impairment (e.g., creatinine clearance <30 mL/min), and concomitant use of potent cytochrome P450 3A4 inhibitors (erythromycin), plasma levels of sildenafil at 24 hours post dose have been found to be 3 to 8 times higher than those seen in healthy volunteers. Although plasma levels of sildenafil at 24 hours post dose are much lower than at peak concentration, it is unknown whether nitrates can be safely coadministered at this time point.
| |
| | |
| VIAGRA is contraindicated in patients with a known hypersensitivity to any component of the tablet.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VIAGRA (SILDENAFIL CITRATE) TABLET, FILM COATED [PFIZER LABORATORIES DIV PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b0be196-0c62-461c-94f4-9a35339b4501 | publisher = | date = | accessdate = 11 March 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]] | |
| [[Category:Drugs]]
| |